Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 5320.0
(1.92%)
KRW 5320.0
(1.92%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 88.59 Billion KRW | -5.07% |
| 2022 | 93.32 Billion KRW | 10.57% |
| 2021 | 84.4 Billion KRW | -3.86% |
| 2020 | 87.79 Billion KRW | 1.46% |
| 2019 | 86.53 Billion KRW | -5.85% |
| 2018 | 91.91 Billion KRW | 11.56% |
| 2017 | 82.38 Billion KRW | 3.34% |
| 2016 | 79.72 Billion KRW | 6.78% |
| 2015 | 74.66 Billion KRW | 2.05% |
| 2014 | 73.15 Billion KRW | -2.68% |
| 2013 | 75.17 Billion KRW | -11.12% |
| 2012 | 84.58 Billion KRW | 7.83% |
| 2011 | 78.44 Billion KRW | 9.06% |
| 2010 | 71.92 Billion KRW | 4.66% |
| 2009 | 68.72 Billion KRW | 10.43% |
| 2008 | 62.23 Billion KRW | 3.17% |
| 2007 | 60.31 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 22.7 Billion KRW | 4.46% |
| 2024 Q2 | 21.74 Billion KRW | -4.27% |
| 2023 Q2 | 23.35 Billion KRW | 8.89% |
| 2023 Q1 | 21.45 Billion KRW | -9.88% |
| 2023 Q4 | 21.73 Billion KRW | -1.39% |
| 2023 FY | 88.59 Billion KRW | -5.07% |
| 2023 Q3 | 22.04 Billion KRW | -5.61% |
| 2022 Q3 | 24.23 Billion KRW | 5.96% |
| 2022 Q4 | 23.8 Billion KRW | -1.8% |
| 2022 FY | 93.32 Billion KRW | 10.57% |
| 2022 Q1 | 22.41 Billion KRW | 7.68% |
| 2022 Q2 | 22.87 Billion KRW | 2.06% |
| 2021 Q3 | 18.32 Billion KRW | -20.19% |
| 2021 Q4 | 20.81 Billion KRW | 13.58% |
| 2021 Q1 | 22.31 Billion KRW | 19.61% |
| 2021 Q2 | 22.95 Billion KRW | 2.91% |
| 2021 FY | 84.4 Billion KRW | -3.86% |
| 2020 Q1 | 22.7 Billion KRW | 10.51% |
| 2020 FY | 87.79 Billion KRW | 1.46% |
| 2020 Q2 | 26.19 Billion KRW | 15.33% |
| 2020 Q3 | 20.24 Billion KRW | -22.69% |
| 2020 Q4 | 18.65 Billion KRW | -7.87% |
| 2019 Q3 | 21.99 Billion KRW | -0.96% |
| 2019 Q2 | 22.2 Billion KRW | 1.94% |
| 2019 Q1 | 21.78 Billion KRW | -1.35% |
| 2019 FY | 86.53 Billion KRW | -5.85% |
| 2019 Q4 | 20.54 Billion KRW | -6.57% |
| 2018 FY | 91.91 Billion KRW | 11.56% |
| 2018 Q2 | 22.35 Billion KRW | 2.09% |
| 2018 Q4 | 22.08 Billion KRW | -13.65% |
| 2018 Q1 | 21.89 Billion KRW | 15.09% |
| 2018 Q3 | 25.57 Billion KRW | 14.4% |
| 2017 FY | 82.38 Billion KRW | 3.34% |
| 2017 Q2 | 21.34 Billion KRW | 5.4% |
| 2017 Q1 | 20.24 Billion KRW | 4.13% |
| 2017 Q4 | 19.02 Billion KRW | -12.61% |
| 2017 Q3 | 21.77 Billion KRW | 2.02% |
| 2016 Q3 | 19.62 Billion KRW | -3.16% |
| 2016 FY | 79.72 Billion KRW | 6.78% |
| 2016 Q4 | 19.44 Billion KRW | -0.94% |
| 2016 Q1 | 20.37 Billion KRW | 8.38% |
| 2016 Q2 | 20.27 Billion KRW | -0.51% |
| 2015 FY | 74.66 Billion KRW | 2.05% |
| 2015 Q4 | 18.8 Billion KRW | 2.58% |
| 2015 Q3 | 18.32 Billion KRW | -4.63% |
| 2015 Q2 | 19.21 Billion KRW | 4.95% |
| 2015 Q1 | 18.31 Billion KRW | 1.85% |
| 2014 FY | 73.15 Billion KRW | -2.68% |
| 2014 Q2 | 18.55 Billion KRW | 2.55% |
| 2014 Q4 | 17.98 Billion KRW | -3.01% |
| 2014 Q3 | 18.53 Billion KRW | -0.06% |
| 2014 Q1 | 18.08 Billion KRW | 7.24% |
| 2013 Q1 | 21.15 Billion KRW | -0.36% |
| 2013 Q2 | 18.57 Billion KRW | -12.21% |
| 2013 Q3 | 18.58 Billion KRW | 0.07% |
| 2013 FY | 75.17 Billion KRW | -11.12% |
| 2013 Q4 | 16.86 Billion KRW | -9.24% |
| 2012 Q4 | 21.23 Billion KRW | 4.81% |
| 2012 Q3 | 20.25 Billion KRW | -5.33% |
| 2012 Q2 | 21.39 Billion KRW | -1.37% |
| 2012 Q1 | 21.69 Billion KRW | 0.0% |
| 2012 FY | 84.58 Billion KRW | 7.83% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 78.44 Billion KRW | 9.06% |
| 2011 Q3 | 19.58 Billion KRW | -2.25% |
| 2011 Q2 | 20.03 Billion KRW | -0.12% |
| 2011 Q1 | 20.06 Billion KRW | 2.12% |
| 2010 Q3 | 17.78 Billion KRW | -1.35% |
| 2010 FY | 71.92 Billion KRW | 4.66% |
| 2010 Q4 | 19.64 Billion KRW | 10.44% |
| 2010 Q1 | 16.45 Billion KRW | -0.26% |
| 2010 Q2 | 18.03 Billion KRW | 9.58% |
| 2009 Q3 | 17.82 Billion KRW | -2.06% |
| 2009 Q1 | 16.19 Billion KRW | 16.79% |
| 2009 FY | 68.72 Billion KRW | 10.43% |
| 2009 Q2 | 18.2 Billion KRW | 12.4% |
| 2009 Q4 | 16.49 Billion KRW | -7.45% |
| 2008 Q2 | 19.27 Billion KRW | 17.13% |
| 2008 Q1 | 16.45 Billion KRW | 28.22% |
| 2008 FY | 62.23 Billion KRW | 3.17% |
| 2008 Q4 | 13.86 Billion KRW | 9.82% |
| 2008 Q3 | 12.62 Billion KRW | -34.51% |
| 2007 Q1 | 15.46 Billion KRW | 0.0% |
| 2007 Q4 | 12.83 Billion KRW | -16.56% |
| 2007 FY | 60.31 Billion KRW | 0.0% |
| 2007 Q2 | 16.63 Billion KRW | 7.54% |
| 2007 Q3 | 15.38 Billion KRW | -7.51% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 35.432% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 92.174% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 86.124% |
| HANDOK Inc. | 522.74 Billion KRW | 83.052% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | 34.556% |
| Yuhan Corporation | 1858.98 Billion KRW | 95.234% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 86.657% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -70.52% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 94.058% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | 34.331% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 76.091% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | 47.753% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 60.53% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 35.432% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -13.504% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | 41.356% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -1.408% |
| JW Holdings Corporation | 928.07 Billion KRW | 90.454% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 85.253% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 94.693% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 88.164% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 55.754% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | 50.989% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 54.879% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 87.804% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 35.432% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 94.15% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 93.558% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 88.164% |
| Yuhan Corporation | 1858.98 Billion KRW | 95.234% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 88.852% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 62.285% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 85.099% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 88.164% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 69.673% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 68.24% |
| CKD Bio Corp. | 160.35 Billion KRW | 44.751% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 83.188% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 75.466% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 61.547% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 55.754% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 89.93% |
| Boryung Corporation | 859.62 Billion KRW | 89.694% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | 29.648% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 76.091% |
| JW Lifescience Corporation | 206.86 Billion KRW | 57.172% |